Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Summary

This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-03

Primary completion

2013-07

Completion

2013-07

Outcome

Missed primary endpoint

paper These results suggest that single agent tivantinib is well tolerated, but did not meet prespecified statistical targets for efficacy. PMID 26123926 ↗

Publications

• Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

Drugs

Indications